Phase 2 was a double-blind study that randomly assigned patients ( 1:1:1 ) using an interactive voice response system to receive rilotumumab 15 mg/kg , rilotumumab 75 mg/kg , or placebo , plus ECX ( doses as above ) , stratified by ECOG performance status and disease extent .